Slv320 manufacturers
- Derenofylline
-
- $42.00 / 5mg
-
2025-04-27
- CAS:251945-92-3
- Min. Order:
- Purity: 99.84%
- Supply Ability: 10g
|
| Product Name: | Slv320 | | Synonyms: | Cyclohexanol, 4-((2-phenyl-1H-pyrrolo(2,3-D)pyrimidin-4-yl)amino)-, trans-;Slv320;trans-4-[(2-Phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclohexanol;(1R,4R)-4-(2-Phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)cyclohexanol;SC-204288;Derenofylline;4-[(2-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclohexanol;SLV320; SLV-320; SLV 320; DERENOFYLLINE | | CAS: | 251945-92-3 | | MF: | C18H20N4O | | MW: | 308.38 | | EINECS: | | | Product Categories: | | | Mol File: | 251945-92-3.mol |  |
| | Slv320 Chemical Properties |
| Boiling point | 532.3±60.0 °C(Predicted) | | density | 1.37±0.1 g/cm3(Predicted) | | storage temp. | Keep in dark place,Sealed in dry,2-8°C | | solubility | Soluble to 100 mM in DMSO and to 50 mM in ethanol | | form | Powder | | pka | 15.15±0.40(Predicted) | | color | White to off-white |
| | Slv320 Usage And Synthesis |
| Description | Derenofylline is an adenosine A1 receptor antagonist (Ki = 1 nM). It is selective for adenosine A1 over A2A, A2B, and A3 receptors (Kis = 398, 3,981, and 200 nM, respectively). It decreases adenosine A1 receptor-mediated adenosine-induced bradycardia in rats (ED50 = 0.49 mg/kg) but reduces A2 receptor-mediated adenosine-induced hypotension by only 44.6% when administered at an intravenous dose of 5 mg/kg. It prevents increases in heart levels of collagen I and III in nephrectomized rats when administered at a dose of 10 mg/kg per day. Derenofylline also reduces relative plaque counts in a Zika virus plaque-forming assay in A549 cells (IC50 = 58.6 nM) in an adenosine A1 receptor-independent manner without inducing cytotoxicity when used at concentrations less than 10 μM. | | Uses | SLV 320 is an A1 antagonist. | | in vivo | Derenofylline (0.3-10 mg/kg, oral administration) suppresses adenosine-induced bradycardia in rats[1].
Derenofylline (10 mg/kg/d, oral administration, 12 weeks) reduces myocardial fibrosis in 5/6 nephrectomy rats without affecting blood pressure[1].
Derenofylline (0.1-5mg/kg, intravenous injection) causes no major haemodynamic effects (heart rate and blood pressure)[1].
| Animal Model: | 5/6 nephrectomy rats[1] | | Dosage: | 10 mg/kg/d | | Administration: | Oral administration, mixed with food for 12 weeks | | Result: | Attenuated urinary albuminuria by about 50%.
Suppressed the increase in CK levels, ALT and AST plasma levels in nephrectomized animals.
|
| | IC 50 | A1R: 1 nM (Ki); Adenosine A3 receptor: 200 nM (Ki); A2AR: 398 nM (Ki) |
| | Slv320 Preparation Products And Raw materials |
|